Galmed is committed to developing innovative therapies for patients with NASH and central to that commitment is the conduct of clinical studies.
We are conducting a Phase 3 study evaluating the safety and effectiveness of the investigational drug Aramchol for the treatment of patients with NASH and liver fibrosis. In some cases, patients may not be eligible to participate in this or other clinical studies.
Galmed is not currently making its investigational drug available for expanded access but may consider doing so once substantial evidence of safety and effectiveness exists for the investigational drug from a positive Phase 3 study.
At that time, Galmed will post its expanded access criteria. For any Galmed expanded access program, the following will always apply:
Galmed will also update this website with any additional criteria and contact information for access requests once it is accepting access requests.
The above is not a guarantee of access to any Galmed investigational drug.